AAV is the top vector choice for use in gene therapies for its stable expression, strong biosafety rating, low immunogenicity, convenient ocular delivery routes and high product stability. Dr. Liu ...
New data publishing 11/11 in Cell Stem Cell provides strong support for the first-in-human universal gene therapy trial for DBA through regulated GATA1 expression ... different genetic mutations with ...
New data publishing 11/11 in Cell Stem Cell provides strong support for the first-in-human universal gene therapy trial for ...
Utilizing a tobacco rattle virus (TRV)-based vector, ... Texas A&M AgriLife researchers uncovered a promising target for controlling gene expression and other cellular processes, which could lead ...
Diamond-Blackfan anemia (DBA) is a potentially life-threatening condition that can cause severe anemia and other abnormalities. It's a rare genetic blood disorder that occurs when the bone marrow ...
Ngangbam PunitaContd from previous issueNotably, Candidatus Liberi-bacterasiaticus is the most destructive and widespread variant, responsible for unprecedented economic losses in global citrus ...
As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...
offering five expression systems: E. coli, Bacillus subtilis, yeast, insect, and mammalian cells. Through codon optimization, vector selection, and high-expression strain screening, Tsingke maximizes ...
Coppernico is applying for permits to increase the drilling capacity at the Sombrero Project by enlarging the permitted area ...
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback